Browse the evidence

Menstrual frequency increased in all groups from baseline to 12 months.

This suggests that while HIT did not specifically improve menstrual frequency, overall menstrual frequency improved over time.

More participants became pregnant in the low-volume HIT (LV-HIT) group compared to the control group.

This indicates that low-volume HIT may have a positive effect on fertility in women with PCOS.

Preoperative semaglutide use in patients with type II diabetes mellitus undergoing arthroscopic rotator cuff repair was associated with a lower incidence of any adverse events (11.0% vs 27.4%), severe adverse events (3.5% vs 10.5%), and minor adverse events (8.5% vs 22.0%) within 90 days post-surgery.

Practitioners may consider semaglutide as a beneficial preoperative intervention to reduce postoperative complications in diabetic patients.

Patients not using semaglutide had a greater odds ratio of experiencing any adverse events (3.65) and severe adverse events (3.62) compared to those using semaglutide.

Highlighting the importance of semaglutide in reducing the risk of complications may guide preoperative decisions.

Patients not using semaglutide had a higher 2-year rotator cuff retear rate (18.3% vs 12.5%) compared to those using semaglutide.

This finding suggests that semaglutide may improve long-term surgical outcomes in diabetic patients.

Gastric motor functions play a significant role in the development of satiation and satiety, impacting weight change.

Understanding gastric functions can help in designing effective weight loss interventions.

Pharmacological agents like liraglutide and dual agonists contribute to weight loss by retarding gastric emptying.

Incorporating GLP-1 agonists may enhance weight loss strategies.

Bariatric surgery and endoscopic gastroplasty alter gastric emptying and incretin responses in markedly divergent manners.

Choosing between surgical options may depend on their differing impacts on gastric function.

Semaglutide differs from other GLP-1 receptor agonists by having a longer half-life and producing greater weight loss.

Semaglutide may offer advantages over other GLP-1 agonists for weight loss due to its pharmacokinetic profile.

GLP-1 receptor agonists and co-agonists were associated with a lower risk of incident atrial fibrillation among individuals with overweight or obesity.

Practitioners may consider GLP-1RAs and co-agonists as potential options for reducing atrial fibrillation risk in overweight or obese patients.

Gynecologists play a pivotal role in the multidisciplinary approach to obesity management during menopause.

Gynecologists should integrate obesity management into routine care for menopausal women.

GLP-1 receptor agonists (GLP-1RAs) and combination therapy led to a significant decrease in mean glycated hemoglobin (HbA1c) levels by −3.5% at 12 months compared to DPP-4 inhibitors.

Practitioners can consider GLP-1RAs and combination therapy as effective options for managing HbA1c in liver transplant recipients with diabetes.

Dual-agonist and tri-agonist administration generally result in greater weight loss compared to GLP-1R agonists used alone.

Practitioners may consider dual- and tri-agonist therapies for enhanced weight loss in patients.

Combination therapies improve blood sugar and lipid levels compared to GLP-1R agonists alone.

Combination therapies may be beneficial for managing blood sugar and lipid levels in patients.

Emerging gut-peptide therapies further improve metabolic health outcomes for various metabolic diseases.

Practitioners should consider gut-peptide therapies for improving metabolic health in patients with metabolic diseases.

In males with type 2 diabetes, an intensive lifestyle intervention increased testosterone levels by 14% at year 1.

Practitioners should be aware of the increase in testosterone levels in males following weight loss interventions.

Changes in waist circumference due to the intensive lifestyle intervention were a significant mediator of sex hormone changes.

Practitioners should consider waist circumference changes when evaluating hormone level changes in patients.

Tirzepatide is approved for the management of type 2 diabetes.

Healthcare providers can consider tirzepatide as a treatment option for patients with type 2 diabetes.

The treatment landscape for glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is evolving.

Practitioners should stay updated on the evolving treatments for diabetes management.

GLP-1 receptor agonists have shown early evidence of cardiovascular benefits in obese patients.

GLP-1 RAs may also be beneficial for cardiovascular health in obese patients.

Tirzepatide reduced the risk of incident major adverse cardiovascular events (MACEs) compared with liraglutide (hazard ratio, 0.58; 95% confidence interval, 0.51–0.66) and semaglutide (0.86; 0.74–0.99).

Practitioners may consider tirzepatide as a more effective option for reducing cardiovascular risks in patients with OSA and T2D.

Tirzepatide was more efficacious in younger, male patients of White ethnicity.

Treatment strategies may need to be tailored based on demographic factors for optimal outcomes.

Tirzepatide reduced incident obstructive sleep apnea (OSA) compared with liraglutide (0.89; 0.82–0.97) but not semaglutide (0.94; 0.86–1.02).

Tirzepatide may be beneficial in managing both diabetes and associated sleep apnea in patients.

GLP-1 agonists had a good safety profile with most adverse effects being mild.

GLP-1 agonists can be considered a safe option for weight management in obese IBD patients.